IVF 2.0

What IVF 2.0 does

IVF 2.0 is a UK-based, privately held embryology innovation organization founded in 2018 by internationally recognized embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. The company builds AI-driven software for fertility clinics, with two core products: SiD (Sperm Identification Device), which uses computer vision to analyze sperm samples and identify optimal cells for IVF procedures, and ERICA (Embryo Ranking Intelligent Classification Assistant), which applies predictive analytics to embryo imaging data to rank and classify embryos for embryologist decision support. Both systems are trained in part on Indian genome sequencing data to localize model precision for Indian patient populations. The company serves a single vertical — IVF clinics and fertility centers — and goes to market as a B2B technology provider rather than a direct-to-patient offering.

IVF 2.0's business model centers on technology licensing or integration with fertility clinic networks. In April 2026, the company entered the Indian market through a flagship partnership with Gaudium IVF and Women Health Ltd, integrating SiD and ERICA into clinical practice as India's first AI-driven infertility treatment program; the launch was inaugurated by Union Minister Nitin Jairam Gadkari. Early clinical observations from this deployment are reported as a 58% first-attempt clinical pregnancy success rate, up to 15% improvement in fertilisation and blastocyst development rates versus standard methods, and a potential 5–7% improvement in first-cycle IVF success rates. The India IVF market is projected to grow from USD 900 million in 2024 to USD 1.87 billion by 2029 at ~15.8% CAGR, providing the company's primary growth runway.

The company operates with 1–10 employees from London and has not publicly disclosed pricing, revenue, or funding rounds. Its near-term commercial profile is concentrated on a single named enterprise customer (Gaudium IVF), creating significant customer concentration risk. With two purpose-built AI products, a credible founder talent base, and a regionally differentiated data approach, IVF 2.0 sits in an early commercialization phase focused on establishing clinical validation and recurring clinic relationships in India before broader geographic or segment expansion.

Name

IVF 2.0

Legal name

IVF 2.0

Website

https://ivf20.ai

Company type

Private

Founded year

2018

Headcount range

1–10 employees

Short description

IVF 2.0 is a UK-based AI software company that builds computer vision and predictive analytics tools — SiD for sperm selection and ERICA for embryo ranking — for IVF clinics. It serves fertility centers, with its flagship deployment at India's Gaudium IVF chain.

Ownership category

akta.pro rank

Product category

AI-Assisted Reproductive Technology

NAICS

Software Publishers (5132), Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD), AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs) (HDAEANAJ), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• AI embryology tools
• IVF success optimization
• Embryo ranking software
• Sperm identification systems
• Fertility clinic AI

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

IVF 2.0 develops AI-driven embryology software for IVF clinics and fertility centers. Its two core products, SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), use computer vision and predictive analytics to optimize sperm selection and embryo ranking, with the aim of improving fertilisation, blastocyst development, and overall IVF success rates.

Product overview

IVF 2.0 is a UK-based embryology innovation organization founded by embryologists Dr. Jacques Cohen and Dr. Alejandro Chave, offering a portfolio of AI-driven embryology tools designed to improve IVF outcomes. The core offerings consist of two integrated AI systems: SiD (Sperm Identification Device) for sperm selection and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo ranking. These tools work together as part of a precision-led approach to infertility treatment, leveraging computer vision and predictive analytics to reduce the emotional and financial burden on patients while improving fertilisation and blastocyst development rates.

Differentiator

Problem solved

Functional benefit

Products and services

• SiD (Sperm Identification Device) An AI-driven sperm identification system that uses computer vision to analyze and select optimal sperm cells for IVF procedures, designed to improve precision in infertility treatment and fertilisation outcomes for IVF clinics and embryologists.
• ERICA (Embryo Ranking Intelligent Classification Assistant) An AI-powered embryo ranking platform that analyzes embryo visual characteristics and developmental potential to classify and rank embryos, helping clinicians select the most viable embryos for transfer and potentially increasing IVF success rates for fertility centers.

Quantifiable outcome

• Up to 15% improvement in fertilisation and blastocyst development rates compared to standard methods
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

One partnership is on record.

• Gaudium IVF and Women Health LtdcoreTechnology or Integration · 1 April 2026IVF 2.0 partnered with Gaudium IVF to introduce AI-led embryology tools including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) into clinical practice. The initiative, inaugurated by Union Minister Nitin Jairam Gadkari, marks India's first AI-driven infertility treatment program. Early clinical observations indicate improved fertilisation rates and blastocyst development rates. The technology aims to improve outcomes while reducing emotional, physical, and financial burden on patients.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• Fairtility: Fairtility offers an AI-based embryo quality assessment platform (CHLOE) used by IVF clinics for transparent, data-driven embryo selection. It directly competes with IVF 2.0's ERICA in the AI embryo-ranking category.
• Alife Health: Alife Health applies AI to fertility treatment decision support, including embryo selection and IVF cycle optimization. It is a direct peer addressing the same clinical pain points (sperm/embryo selection precision) with an AI software model.
• Presagen: Presagen builds AI healthcare products with a focus on women's health and fertility, including embryo and oocyte assessment. It overlaps with IVF 2.0 in applying AI to reproductive medicine workflows.
• AIVF: AIVF develops AI-based clinical decision support for IVF clinics, including embryo evaluation tools. It is the closest direct competitor to IVF 2.0's SiD and ERICA offerings, serving the same fertility clinic customer base with computer-vision-driven IVF optimization.
• Life Whisperer (Vitrolife): Life Whisperer provides AI-based embryo and sperm viability assessment, now part of Vitrolife. It is a direct competitor to IVF 2.0 in AI-driven gamete and embryo selection.

Broad incumbents

• Vitrolife: Vitrolife is a global provider of IVF media, consumables, and increasingly AI-enabled tools (via Life Whisperer). It is a broad incumbent in fertility whose portfolio overlaps with IVF 2.0's clinical decision support.
• CooperSurgical (CooperCompanies): CooperSurgical is a major provider of fertility and women's health products, including IVF lab equipment and media. As a broad incumbent with deep clinic relationships, it represents both a competitive threat and a potential exit partner for IVF 2.0.
• Genea Biomedx: Genea Biomedx develops IVF lab devices and software (e.g., Geri time-lapse incubator, Gems embryo culture). It is an incumbent in AI-enabled embryo monitoring and a relevant comparability anchor for IVF 2.0's clinical tooling.
• Hamilton Thorne: Hamilton Thorne provides precision instruments, image-based systems, and AI/disposable products for the IVF and reproductive research markets. It is a broad incumbent whose imaging and analysis systems compete with IVF 2.0's computer-vision approach.

Emerging players

• Univfy: Univfy uses predictive analytics to provide personalized IVF success probability reports, helping clinics with patient counseling. It is an emerging player in AI for IVF decision support with adjacent rather than direct overlap to IVF 2.0.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IVF 2.0